OPTIMIZING POSTBIOTIC THERAPY: THE THERAPEUTIC ADVANTAGES AND PHARMACEUTICAL STABILIZATION OF SODIUM BUTYRATE

Postbiotics represent a rapidly evolving edge in microbiome therapy, yet significant differences exist in their stability, safety, and pharmacokinetics. This review outlines how Sodium Butyrate (SB) scores over alternative postbiotics such as heat-killed bacterial lysates, cell-wall fragments, and other short-chain fatty acids like acetate and propionate due to its high tissue-specificity, predictable safety profile, and dual intracellular signaling mechanisms. While acetate and propionate are quickly absorbed into systemic circulation, 70-90% of luminal butyrate is consumed directly by the colonic epithelium to fuel and repair the mucosal barrier. Furthermore, as a defined chemical salt, SB completely avoids the endotoxin risks and batch-to-batch variability inherent to raw bacterial lysates. Finally, this paper highlights the industrial standardization achieved by West Bengal Chemical Industries Ltd., Kolkata, India (WBCIL). WBCIL’s advanced microencapsulation (offering 30%, 60%, and 90% matrices) and target-release granular technologies successfully neutralize the volatile odor of raw butyric acid while ensuring uniform, pH-dependent delivery to the lower gastrointestinal tract under strict WHO-GMP compliance.